Preferred Label : indoles;

MeSH definition : Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.;

Wikipedia automatic translation : Indole;

Wikipedia link : https://en.wikipedia.org/wiki/Indole;

Codes EINECS : 204-420-7;

Is substance : O;

Details


Main resources

You can consult :

Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.

https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/default-d6182e9e12-99.html
2021
false
false
false
Canada
French
drug evaluation
quebec
cystic fibrosis
adolescent
adult
cystic fibrosis with F508del mutation in the cystic fibrosis transmembrane conductance regulator gene
CFTR delta F508
drug combinations
trikafta
elexacaftor, ivacaftor, tezacaftor drug combination
elexacaftor, ivacaftor, tezacaftor drug combination
benzodioxoles
aminophenols
indoles
pyrazoles
pyridines
quinolines
benzodioxoles
aminophenols
drug combinations
indoles
pyrazoles
pyridines
quinolines

---
https://www.ema.europa.eu/en/medicines/human/EPAR/symkevi
2021
false
false
false
Netherlands
French
English
drug approval
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug combinations
tezacaftor, ivacaftor drug combination
tezacaftor
tezacaftor
ivacaftor
ivacaftor
administration, oral
ivacaftor and tezacaftor
Chloride Channel Agonists
Chloride Channel Agonists
cystic fibrosis
drug interactions
pregnancy
breast feeding
child
adolescent
adult
orphan drug production
drug monitoring
cystic fibrosis with F508del mutation in the cystic fibrosis transmembrane conductance regulator gene
aged
drug evaluation, preclinical
aminophenols
indoles
quinolones
benzodioxoles
indoles
benzodioxoles
indoles
benzodioxoles
aminophenols
quinolones
aminophenols
quinolones

---
https://www.has-sante.fr/jcms/p_3225416/fr/ofev-pid-scs-chez-l-adulte
2021
false
false
false
France
French
insurance, health, reimbursement
treatment outcome
evaluation of the transparency committee
nintedanib
enzyme inhibitors
protein-tyrosine kinases
administration, oral
adult
lung diseases, interstitial
scleroderma, systemic
nintedanib
interstitial lung disease associated with systemic sclerosis
Tyrosine Kinase Inhibitors
indoles

---
https://www.has-sante.fr/jcms/p_3225386/fr/ofev-pid
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
nintedanib
administration, oral
enzyme inhibitors
protein-tyrosine kinases
lung diseases, interstitial
guidelines for drug use
chronic disease
progressive fibrosing interstitial lung disease
Tyrosine Kinase Inhibitors
evaluation of the transparency committee
nintedanib
indoles

---
https://www.has-sante.fr/jcms/p_3282752/fr/symkevi-100-mg/150-mg-ivacaftor/-tezacaftor-mucoviscidose-6-ans
2021
false
false
false
France
evaluation of the transparency committee
aminophenols
drug combinations
indoles
quinolones
benzodioxoles
child
adolescent
cystic fibrosis with F508del mutation in the cystic fibrosis transmembrane conductance regulator gene
cystic fibrosis
tezacaftor, ivacaftor drug combination
tezacaftor
ivacaftor
ivacaftor and tezacaftor
drug therapy, combination
treatment outcome
insurance, health, reimbursement
administration, oral

---
https://www.ema.europa.eu/en/medicines/human/EPAR/kaftrio
2020
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Product containing only elexacaftor and ivacaftor and tezacaftor in oral dose form (medicinal product form)
drug approval
europe
drug combinations
administration, oral
orphan drug production
pyrazoles
pyrazoles
pyridines
pyridines
pyrrolidines
pyrrolidines
ivacaftor
ivacaftor
tezacaftor
tezacaftor
adolescent
adult
cystic fibrosis
drug therapy, combination
cystic fibrosis transmembrane conductance regulator
ivacaftor, tezacaftor and elexacaftor
product surveillance, postmarketing
drug interactions
drug evaluation, preclinical
elexacaftor, ivacaftor, tezacaftor drug combination
elexacaftor, ivacaftor, tezacaftor drug combination
elexacaftor
elexacaftor
cystic fibrosis with F508del mutation in the cystic fibrosis transmembrane conductance regulator gene
aminophenols
quinolones
aminophenols
quinolones
indoles
benzodioxoles
indoles
benzodioxoles
quinolines
quinolines

---
https://www.has-sante.fr/jcms/p_3220388/fr/kaftrio-/-kalydeco
2020
false
false
false
France
drug combinations
treatment outcome
insurance, health, reimbursement
ivacaftor
Chloride Channel Agonists
tezacaftor
ivacaftor
ivacaftor, tezacaftor and elexacaftor
cystic fibrosis
adolescent
adult
CFTR delta F508
cystic fibrosis transmembrane conductance regulator delta F508
administration, oral
elexacaftor
elexacaftor, ivacaftor, tezacaftor drug combination
evaluation of the transparency committee
aminophenols
quinolones
indoles
benzodioxoles
cystic fibrosis transmembrane conductance regulator
pyrrolidines
pyridines
pyrazoles
drug combinations
quinolines

---
https://www.has-sante.fr/jcms/p_3184439/fr/symkevi-/-kalydeco
2020
false
false
false
France
drug combinations
administration, oral
insurance, health, reimbursement
ivacaftor and tezacaftor
ivacaftor
cystic fibrosis
adolescent
Product containing only ivacaftor and tezacaftor in oral dose form (medicinal product form)
tezacaftor
CFTR delta F508
treatment outcome
cystic fibrosis with F508del mutation in the cystic fibrosis transmembrane conductance regulator gene
tezacaftor, ivacaftor drug combination
evaluation of the transparency committee
ivacaftor
aminophenols
quinolones
aminophenols
quinolones
indoles
benzodioxoles

---
https://www.has-sante.fr/jcms/p_3112630/fr/rubraca
2020
false
false
false
France
rucaparib
rucaparib
administration, oral
treatment outcome
insurance, health, reimbursement
ovarian neoplasms
fallopian tube neoplasms
peritoneal neoplasms
adult
Poly(ADP-ribose) Polymerase Inhibitors
evaluation of the transparency committee
indoles

---
https://www.ema.europa.eu/en/medicines/human/EPAR/macimorelin-aeterna-zentaris
2019
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
diagnostic uses of chemicals
drug approval
europe
macimorelin
Decreased response to growth hormone stimulation test
human growth hormone
adult
administration, oral
pituitary gland
drug interactions
pregnancy
breast feeding
macimorelin
indoles
tryptophan

---
https://www.ema.europa.eu/en/medicines/human/EPAR/silodosin-recordati
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
prostatic hyperplasia
administration, oral
silodosin
silodosin
silodosin
adrenergic alpha-1 receptor antagonists
adrenergic alpha-1 receptor antagonists
urological agents
urological agents
adult
aged
drug interactions
fertility
drug evaluation, preclinical
indoles
indoles

---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00402
2018
false
false
false
Canada
French
drug information
administration, oral
drug approval
canada
ivacaftor and tezacaftor
drug combinations
tezacaftor
tezacaftor
ivacaftor
ivacaftor
cystic fibrosis
adolescent
adult
cystic fibrosis
cystic fibrosis transmembrane conductance regulator
mutation
treatment outcome
indoles
benzodioxoles
indoles
benzodioxoles
aminophenols
quinolones
aminophenols
quinolones
tezacaftor, ivacaftor drug combination

---
https://www.pharmactuel.com/index.php/pharmactuel/article/view/1209
2018
false
false
false
Canada
French
journal article
treatment outcome
disease-free survival
carfilzomib
elotuzumab
daratumumab
antineoplastic agents
antineoplastic agents
ixazomib
recurrence
multiple myeloma
oligopeptides
antibodies, monoclonal, humanized
antibodies, monoclonal
boron compounds
glycine
glycine
indoles
hydroxamic acids
Panobinostat

---
https://ansm.sante.fr/informations-de-securite/zelboraf-cotellic-v-rappel-du-risque-datteintes-opthalmiques-et-de-leur-prise-en-charge
2018
false
false
false
France
French
pharmacovigilance note
retinal diseases
vision disorders
cobimetinib
continuity of patient care
mass screening
risk
guidelines for drug use
pharmacovigilance
uveitis
cobimetinib
indoles
sulfonamides
azetidines
piperidines
Vemurafenib

---
https://www.ema.europa.eu/medicines/human/EPAR/Rubraca
2018
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
rucaparib
drug approval
europe
treatment outcome
rucaparib
orphan drug production
ovarian neoplasms
fallopian tube neoplasms
peritoneal neoplasms
adult
mutation
fallopian tube neoplasms
ovarian neoplasms
peritoneal neoplasms
administration, oral
tablets
Poly(ADP-ribose) Polymerase Inhibitors
Poly(ADP-ribose) Polymerase Inhibitors
product surveillance, postmarketing
drug monitoring
drug interactions
pregnancy
breast feeding
genes, BRCA1
genes, BRCA2
drug evaluation, preclinical
rucaparib
indoles
indoles
indoles

---
http://conseil-scientifique.public.lu/fr/publications/oncologie/vemurafenib-mise-a-jour-2018.html
2018
false
false
true
Luxembourg
French
administration, oral
vemurafenib
guidelines for drug use
BRAF protein, human
protein kinase inhibitors
melanoma
neoplasm metastasis
Metastatic Melanoma
BRAF V600E Mutation Present
Unresectable Malignant Neoplasm
adult
antineoplastic combined chemotherapy protocols
Off-Label use
mutation
melanoma
indoles
sulfonamides
proto-oncogene proteins b-raf
Vemurafenib

---
OFEV (nintedanib) - Risk of Drug-Induced Liver Injury and the Need for Regular Monitoring of Liver Function
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2018/65670a-fra.php
2018
false
false
false
Canada
French
English
pharmacovigilance note
administration, oral
nintedanib
nintedanib
drug monitoring
continuity of patient care
Chemical and Drug Induced Liver Injury
Chemical and Drug Induced Liver Injury
liver function tests
transaminases
bilirubin
idiopathic pulmonary fibrosis
nintedanib esylate
indoles

---
http://www.has-sante.fr/portail/jcms/c_2755482/fr/zelboraf
2017
false
false
false
France
French
evaluation of the transparency committee
insurance, health, reimbursement
treatment outcome
indoles
sulfonamides
Vemurafenib

---
http://orbi.ulg.ac.be/handle/2268/210429
2017
false
false
false
Belgium
French
idiopathic pulmonary fibrosis
nintedanib
journal article
clinical trials, phase iii as topic
treatment outcome
administration, oral
enzyme inhibitors
quality of life
idiopathic pulmonary fibrosis
nintedanib
enzyme inhibitors
belgium
insurance, health, reimbursement
protein-tyrosine kinases
Tyrosine Kinase Inhibitors
indoles
indoles

---
https://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/hpiw-ivps_2016-12-fra.php#zelb
2016
false
false
false
Canada
French
English
drug evaluation
risk assessment
vemurafenib
vemurafenib
melanoma
neoplasm metastasis
protein kinase inhibitors
anemia, aplastic
bone marrow
aplastic anemia secondary to chemicals
product surveillance, postmarketing
indoles
sulfonamides
Vemurafenib

---
http://www.conseil-scientifique.public.lu/fr/publications/oncologie/sunitinib.html
2016
false
false
true
Luxembourg
French
guidelines for drug use
antineoplastic agents
administration, oral
sunitinib
protein kinase inhibitors
receptor Protein-Tyrosine kinases
treatment outcome
survival analysis
Progression-Free survival
kidney neoplasms
neoplasm metastasis
Metastatic Kidney Carcinoma
adult
gastrointestinal stromal tumors
pancreatic neoplasms
Pancreatic Neuroendocrine Tumor
neuroendocrine tumors
Advanced Malignant Neoplasm
Unresectable Malignant Neoplasm
Tyrosine Kinase Inhibitors
disease-free survival
indoles
pyrroles
Sunitinib

---
http://www.conseil-scientifique.public.lu/fr/publications/oncologie/nintedanib.html
2016
false
false
true
Luxembourg
French
guidelines for drug use
nintedanib
antineoplastic agents
protein-tyrosine kinases
protein kinase inhibitors
neoplasm metastasis
Stage IV Lung Adenocarcinoma AJCC v7
administration, oral
antineoplastic combined chemotherapy protocols
treatment outcome
survival analysis
Progression-Free survival
Tyrosine Kinase Inhibitors
nintedanib
indoles
disease-free survival
adenocarcinoma
lung neoplasms
taxoids
Docetaxel
Adenocarcinoma of Lung

---
http://www.has-sante.fr/portail/jcms/c_2628641/fr/farydak
2016
false
false
false
France
French
treatment outcome
orphan drug production
panobinostat
antineoplastic agents
antineoplastic combined chemotherapy protocols
dexamethasone
adult
administration, oral
multiple myeloma
Refractory Multiple Myeloma
Recurrent Multiple Myeloma
histone deacetylase inhibitors
aged
Bortezomib
evaluation of the transparency committee
insurance, health, reimbursement
indoles
hydroxamic acids
Panobinostat

---
http://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Medicaments-ciblant-BRAF-en-monotherapie-vemurafenib-dabrafenib-Medicaments-ciblant-BRAF-ou-MEK-en-association-vemurafenib-cobimetinib-dabrafenib-trametinib
2016
false
false
false
France
French
guidelines for drug use
practice guideline
patients guideline
protein kinase inhibitors
protein kinase inhibitors
Drug-Related side effects and adverse reactions
administration, oral
drug interactions
vemurafenib
vemurafenib
antineoplastic combined chemotherapy protocols
vemurafenib
dabrafenib
dabrafenib
dabrafenib
BRAF protein, human
Metastatic Melanoma
melanoma
melanoma
neoplasm metastasis
BRAF Gene Mutation
continuity of patient care
drug monitoring
interdisciplinary communication
protein kinase inhibitors
vemurafenib
dabrafenib
pregnancy
imidazoles
oximes
imidazoles
oximes
proto-oncogene proteins b-raf
imidazoles
oximes
indoles
sulfonamides
indoles
sulfonamides
indoles
sulfonamides
Vemurafenib
Vemurafenib
Vemurafenib

---
ZELBORAF (vemurafenib) - Risk of Radiation Sensitization or Radiation Recall Reaction
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2015/56368a-fra.php
2015
false
false
false
Canada
French
English
pharmacovigilance note
radiation injuries
melanoma
melanoma
vemurafenib
vemurafenib
radiotherapy
adult
BRAF V600E Mutation Present
chemoradiotherapy
indoles
sulfonamides
Vemurafenib

---
Skin-cancer drug Zelboraf (vemurafenib): new warning on the risk of pancreatitis
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2015/43697a-fra.php
2015
false
false
false
Canada
French
English
pancreatitis
pharmacovigilance note
vemurafenib
vemurafenib
melanoma
protein kinase inhibitors
vemurafenib
adult
protein kinase inhibitors
Drug-induced acute pancreatitis (disorder)
indoles
sulfonamides
indoles
sulfonamides
Vemurafenib
Vemurafenib

---
http://www.has-sante.fr/portail/jcms/c_2048057/fr/vargatef
http://www.has-sante.fr/portail/jcms/c_2048057/fr/vargatef-nintedanib-inhibiteur-de-tyrosine-kinase
2015
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
administration, oral
nintedanib
nintedanib
nintedanib esylate
nintedanib esylate
antineoplastic combined chemotherapy protocols
antineoplastic agents
antineoplastic agents
adenocarcinoma
carcinoma, non-small-cell lung
adult
neoplasm metastasis
Locally Advanced Malignant Neoplasm
neoplasm recurrence, local
insurance, health, reimbursement
enzyme inhibitors
enzyme inhibitors
receptors, fibroblast growth factor
receptors, platelet-derived growth factor
receptors, vascular endothelial growth factor
nintedanib
guidelines for drug use
Tyrosine Kinase Inhibitors
indoles
indoles

---
https://www.ema.europa.eu/medicines/human/EPAR/Farydak
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
orphan drug production
panobinostat
drug approval
europe
drug monitoring
product surveillance, postmarketing
antineoplastic agents
antineoplastic agents
antineoplastic combined chemotherapy protocols
dexamethasone
adult
administration, oral
multiple myeloma
Progression of Multiple Myeloma or Plasma Cell Leukemia
Refractory Multiple Myeloma
Recurrent Multiple Myeloma
histone deacetylase inhibitors
histone deacetylase inhibitors
pregnancy
breast feeding
aged
drug interactions
survival analysis
drug evaluation, preclinical
Bortezomib
indoles
hydroxamic acids
indoles
hydroxamic acids
Panobinostat
Panobinostat

---
oestrogens conjugated / bazedoxifene
https://www.ema.europa.eu/medicines/human/EPAR/Duavive
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug combinations
bazedoxifene
bazedoxifene
estrogens, conjugated (usp)
estrogens, conjugated (usp)
estrogens
estrogens
drug approval
europe
Delayed-Action preparations
administration, oral
selective estrogen receptor modulators
selective estrogen receptor modulators
hot flashes
menopause
postmenopause
risk management
drug monitoring
product surveillance, postmarketing
continuity of patient care
drug interactions
breast feeding
clinical trials as topic
drug evaluation, preclinical
conjugated estrogens and bazedoxifene
estrogen replacement therapy
indoles
indoles

---
https://www.ema.europa.eu/medicines/human/EPAR/Vargatef
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
nintedanib
nintedanib
drug approval
europe
antineoplastic agents
antineoplastic agents
adult
carcinoma, non-small-cell lung
neoplasm metastasis
adenocarcinoma
antineoplastic combined chemotherapy protocols
administration, oral
enzyme inhibitors
enzyme inhibitors
aged
drug interactions
pregnancy
contraception
breast feeding
protein-tyrosine kinases
drug evaluation, preclinical
nintedanib
Tyrosine Kinase Inhibitors
indoles
indoles
taxoids
Docetaxel

---
http://www.has-sante.fr/portail/jcms/c_2038122/fr/ofev
http://www.has-sante.fr/portail/jcms/c_2038122/fr/ofev-nintedanib-inhibiteur-des-tyrosines-kinases
2015
false
false
false
France
French
evaluation of the transparency committee
administration, oral
treatment outcome
insurance, health, reimbursement
nintedanib esylate
nintedanib esylate
idiopathic pulmonary fibrosis
adult
orphan drug production
enzyme inhibitors
enzyme inhibitors
protein-tyrosine kinases
guidelines for drug use
nintedanib
Tyrosine Kinase Inhibitors
nintedanib
nintedanib
indoles
indoles

---
https://www.ema.europa.eu/medicines/human/EPAR/Ofev
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
nintedanib
nintedanib
orphan drug production
adult
drug approval
europe
idiopathic pulmonary fibrosis
administration, oral
enzyme inhibitors
enzyme inhibitors
protein-tyrosine kinases
risk management
drug monitoring
nintedanib
lung diseases, interstitial
interstitial lung disease associated with systemic sclerosis
progressive fibrosing interstitial lung disease
Tyrosine Kinase Inhibitors
indoles
indoles

---
https://webprod.hc-sc.gc.ca/nhpid-bdipsn/atReq?atid=indole3carbinol&lang=fra
2014
false
false
false
Canada
French
drug information
indoles
indole
office visits
indole
consultation, nos
consultation
referral and consultation

---
http://www.pharmactuel.com/index.php/pharmactuel/article/view/904
2013
false
France
French
Stage IV Cutaneous Melanoma AJCC v6 and v7
melanoma, cutaneous malignant
melanoma
neoplasm metastasis
skin neoplasms
journal article
antineoplastic agents
antineoplastic agents
antibodies, monoclonal
indoles
sulfonamides
melanoma
Vemurafenib
Vemurafenib

---
Tredaptive - nicotinic acid / laropiprant
This medicine is now withdrawn from use in the European Union
https://www.ema.europa.eu/medicines/human/EPAR/Tredaptive
2012
false
United Kingdom
English
French
syndication feed
Primary hypercholesterolemia (disorder)
mixed dyslipidemia
niacin
hypolipidemic agents
indoles
dyslipidemias
drug approval
drug labeling
treatment outcome
drug combinations
drug therapy, combination
indoles
hypolipidemic agents
niacin
tablets
administration, oral
hypercholesterolemia
adult
aged
drug interactions
breast feeding
drug evaluation, preclinical
MK-0524
MK-0524
nicotinic acid, combinations
laropiprant
laropiprant
drug evaluation
summary of product characteristics
package leaflet

---
Trevaclyn - nicotinic acid / laropiprant
https://www.ema.europa.eu/medicines/human/EPAR/Trevaclyn
2012
false
United Kingdom
French
English
syndication feed
Primary hypercholesterolemia (disorder)
mixed dyslipidemia
niacin
dyslipidemias
indoles
hypolipidemic agents
hypolipidemic agents
niacin
indoles
adult
aged
tablets
administration, oral
drug combinations
drug therapy, combination
drug interactions
drug approval
drug labeling
pregnancy
breast feeding
treatment outcome
hypercholesterolemia
MK-0524
MK-0524
nicotinic acid, combinations
laropiprant
laropiprant
drug evaluation
summary of product characteristics
package leaflet

---
Pelzont - nicotinic acid / laropiprant
https://www.ema.europa.eu/medicines/human/EPAR/Pelzont
2012
false
United Kingdom
English
French
syndication feed
Primary hypercholesterolemia (disorder)
mixed dyslipidemia
pregnancy
breast feeding
treatment outcome
adult
aged
drug interactions
drug evaluation, preclinical
drug therapy, combination
hypercholesterolemia
niacin
indoles
dyslipidemias
hypolipidemic agents
drug combinations
niacin
indoles
hypolipidemic agents
administration, oral
tablets
drug approval
drug labeling
MK-0524
MK-0524
nicotinic acid, combinations
laropiprant
laropiprant
drug evaluation
summary of product characteristics
package leaflet

---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailOne.php?lang=fr&linkID=SBD00164
2012
false
false
false
Canada
vemurafenib
Product containing vemurafenib (medicinal product)
drug information
indoles
sulfonamides
Vemurafenib

---
http://www.has-sante.fr/portail/jcms/c_1355322/zelboraf-vemurafenib-inhibiteur-de-la-proteine-kinase-braf
http://www.has-sante.fr/portail/jcms/c_1355321/zelboraf-synthese-ct12121
2012
France
French
melanoma
evaluation of the transparency committee
guidelines for drug use
vemurafenib
indoles
sulfonamides
proto-oncogene proteins b-raf
Vemurafenib

---
http://www.cochrane.org/fr/CD001715
2011
false
true
false
France
United Kingdom
indoles
imidazoles
treatment outcome
review of literature
french abstract
sertindole
schizophrenia

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=63021036
2009
France
French
fatty acids, monounsaturated
indoles
anticholesteremic agents
hydroxymethylglutaryl-coa reductase inhibitors
summary of product characteristics
package leaflet

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=60477853
2009
France
French
indoles
fatty acids, monounsaturated
anticholesteremic agents
hydroxymethylglutaryl-coa reductase inhibitors
summary of product characteristics
package leaflet

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=63550908
2009
France
French
indoles
fatty acids, monounsaturated
anticholesteremic agents
hydroxymethylglutaryl-coa reductase inhibitors
summary of product characteristics
package leaflet

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=69366822
2009
France
French
indoles
anticholesteremic agents
hydroxymethylglutaryl-coa reductase inhibitors
fatty acids, monounsaturated
drug information

---
http://medecine-pharmacie.univ-rouen.fr/jsp/saisie/liste_fichiergw.jsp?OBJET=DOCUMENT&CODE=1254492286277&LANGUE=0
http://medecine-pharmacie.univ-rouen.fr/servlet/com.univ.collaboratif.utils.LectureFichiergw?ID_FICHIER=11807
1998
false
true
false
false
France
parkinson disease
ropinirole
levodopa
critical appraisal or critical reading
parkinson disease
indoles

---
Nous contacter.
25/04/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.